Evidence map›Paper›PMID 37563642›Full record

ArticleRetrovirology2023

Transmitted/founder SHIV.D replicates in the brain, causes neuropathogenesis, and persists on combination antiretroviral therapy in rhesus macaques.

Rachel M Podgorski, Jake A Robinson, Mandy D Smith, Suvadip Mallick, Huaqing Zhao, Ronald S Veazey, Dennis L Kolson, Katharine J Bar, Tricia H Burdo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Retrovirology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Rachel M PodgorskiCenter for NeuroVirology and Gene Editing, Department of Microbiology, Immunology, and Inflammation, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
Jake A RobinsonCenter for NeuroVirology and Gene Editing, Department of Microbiology, Immunology, and Inflammation, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
Mandy D SmithCenter for NeuroVirology and Gene Editing, Department of Microbiology, Immunology, and Inflammation, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
Suvadip MallickDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Huaqing ZhaoCenter for Biostatistics and Epidemiology, Department of Biomedical Education and Data Science, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
Ronald S VeazeyTulane National Primate Research Center, Tulane School of Medicine, Covington, LA, USA.
Dennis L KolsonDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Katharine J BarDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. bark@pennmedicine.upenn.edu.
Tricia H BurdoCenter for NeuroVirology and Gene Editing, Department of Microbiology, Immunology, and Inflammation, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA. burdot@temple.edu.
Temple University · USUniversity of Pennsylvania · USTulane University · US

Funding

Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4M
Virus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Ronald G Collman · 1999 to 2026
$78.6M
Viral Gene Editing and Bioinformatics Core for Institution # 269291P30MH092177 · NIMH · TEMPLE UNIV OF THE COMMONWEALTH · PI Ilker Kudret Sariyer · 2011 to 2026
$24.9M
First-in-human study of two anti-SARS CoV-2 antibodies in health volunteersUM1AI126620 · NIAID · WISTAR INSTITUTE · PI MONTANER, LUIS J, RILEY, JAMES L. · 2016 to 2021
$24.5M
Collaboratory of AIDS Researchers for Eradication (CARE)UM1AI126619 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MARGOLIS, DAVID M. · 2016 to 2020
$23.2M
Project 2 - Michael BettsP01AI131338 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI BETTS, MICHAEL R · 2017 to 2021
$7.8M
Interdisciplinary And Translational Research Training In NeurohivT32MH079785 · NIMH · TEMPLE UNIV OF THE COMMONWEALTH · PI Kamel Khalili · 2008 to 2026
$5.4M
Novel macrophage-tropic transmitted/founder SHIV model of CNS persistence to evaluate CRISPR/Cas9 gene editingR01MH128155 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI BAR, KATHARINE JUNE, BURDO, TRICIA HELEN · 2021 to 2025
$4.7M
Characterizing the viral and host effector mechanisms that govern HIV-1 reboundR01AI162646 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI BAR, KATHARINE JUNE, HAHN, BEATRICE H · 2021 to 2025
$4.1M
Determining the effects of broadly neutralizing antibodies at antiretroviral therapy initiationR01AI179666 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Katharine June Bar, Mirko Paiardini · 2023 to 2026
$3.4M
NIAID NIH HHS P01 AI131338NIAID NIH HHS P30 AI045008NIAID NIH HHS R01 AI162646NIAID NIH HHS R01 AI179666NIAID NIH HHS UM1 AI126619NIAID NIH HHS UM1 AI126620NIH HHS P51 OD011104NIMH NIH HHS P30 MH092177NIMH NIH HHS R01 MH128155NIMH NIH HHS T32 MH079785
6 · The paper itself

Abstract

A biologically relevant non-human primate (NHP) model of HIV persistence in the central nervous system (CNS) is necessary. Most current NHP/SIV models of HIV infection fail to recapitulate viral persistence in the CNS without encephalitis or fail to employ viruses that authentically represent the ongoing HIV-1 pandemic. Here, we demonstrate viral replication in the brain and neuropathogenesis after combination antiretroviral therapy (ART) in rhesus macaques (RMs) using novel macrophage-tropic transmitted/founder (TF) simian-human immunodeficiency virus SHIV.D.191,859 (SHIV.D). Quantitative immunohistochemistry (IHC) and DNA/RNAscope in situ hybridization (ISH) were performed on three brain regions from six SHIV.D-infected RMs; two necropsied while viremic, two during analytical treatment interruptions, and two on suppressive ART. We demonstrated myeloid-mediated neuroinflammation, viral replication, and proviral DNA in the brain in all animals. These results demonstrate that TF SHIV.D models native HIV-1 CNS replication, pathogenesis, and persistence on ART in rhesus macaques.

Indexed as

HIV-1HIV InfectionsSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusAnimalsAntiretroviral Therapy, Highly ActiveBrainHumansMacaca mulattaViral LoadVirus ReplicationHIVNeuroHIVNon-human primatesPersistenceSHIV

Identifiers

PMID37563642
PMCPMC10413509
OpenAlexW4385740425

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.